AIM: To test the hypothesis that an improving body composition in insulin-resistant individuals could enhance insulin sensitivity. METHODS: A total of 16 people with a mean body mass index of 29.3 kg/m2 and insulin resistance, received a single dose of bimagrumab or placebo and were assessed at week 10 for insulin sensitivity, using a hyperinsulinaemic-euglycaemic clamp and an intravenous glucose tolerance test (IVGTT), and for body composition using dual energy X-ray absorptiometry and positron-emission tomography. RESULTS:Bimagrumab increased lean mass by 2.7% (P < .05) and reduced fat mass by 7.9% (P = .011) at week 10 compared with placebo, and had a neutral effect on body weight. Bimagrumab reduced glycated haemoglobin by 0.21% at week 18 (P < .001) and improved insulin sensitivity by ~20% (according to the clamp) to ~40% (according to the IVGTT). CONCLUSION: Taking the observed changes together, and given that these occurred without accompanying dietary intervention and without any prescribed regular physical exercise, bimagrumab may offer a novel approach for the treatment of the metabolic complications of obesity.
RCT Entities:
AIM: To test the hypothesis that an improving body composition in insulin-resistant individuals could enhance insulin sensitivity. METHODS: A total of 16 people with a mean body mass index of 29.3 kg/m2 and insulin resistance, received a single dose of bimagrumab or placebo and were assessed at week 10 for insulin sensitivity, using a hyperinsulinaemic-euglycaemic clamp and an intravenous glucose tolerance test (IVGTT), and for body composition using dual energy X-ray absorptiometry and positron-emission tomography. RESULTS:Bimagrumab increased lean mass by 2.7% (P < .05) and reduced fat mass by 7.9% (P = .011) at week 10 compared with placebo, and had a neutral effect on body weight. Bimagrumab reduced glycated haemoglobin by 0.21% at week 18 (P < .001) and improved insulin sensitivity by ~20% (according to the clamp) to ~40% (according to the IVGTT). CONCLUSION: Taking the observed changes together, and given that these occurred without accompanying dietary intervention and without any prescribed regular physical exercise, bimagrumab may offer a novel approach for the treatment of the metabolic complications of obesity.
Authors: Rosamund C Smith; Martin S Cramer; Pamela J Mitchell; Jonathan Lucchesi; Alicia M Ortega; Eric W Livingston; Darryl Ballard; Ling Zhang; Jeff Hanson; Kenneth Barton; Shawn Berens; Kelly M Credille; Ted A Bateman; Virginia L Ferguson; Yanfei L Ma; Louis S Stodieck Journal: PLoS One Date: 2020-04-21 Impact factor: 3.240
Authors: Xiuqing Han; Lisbeth Liliendal Valbjørn Møller; Estelle De Groote; Kirstine Nyvold Bojsen-Møller; Jonathan Davey; Carlos Henríquez-Olguin; Zhencheng Li; Jonas Roland Knudsen; Thomas Elbenhardt Jensen; Sten Madsbad; Paul Gregorevic; Erik Arne Richter; Lykke Sylow Journal: J Cachexia Sarcopenia Muscle Date: 2019-08-11 Impact factor: 12.910
Authors: Mohamed A Alfaleh; Hashem O Alsaab; Ahmad Bakur Mahmoud; Almohanad A Alkayyal; Martina L Jones; Stephen M Mahler; Anwar M Hashem Journal: Front Immunol Date: 2020-08-28 Impact factor: 7.561